Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Jasper Therapeutics, retaining the price target of $20.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Emily Bodnar’s rating is based on Jasper Therapeutics’ promising clinical data and strategic focus. The company has reported strong efficacy results for its drug briquilimab in treating chronic spontaneous urticaria (CSU), with a high percentage of patients achieving complete response in clinical trials. This positive outcome, along with a favorable safety profile, supports the potential of briquilimab as a viable treatment option.
Additionally, Jasper Therapeutics has undertaken significant corporate restructuring to concentrate its resources on urticaria, demonstrating a clear strategic direction. Despite some challenges related to product lot variability, the company is actively addressing these issues and plans to provide further updates on dosing regimens and additional patient data. These efforts, combined with the robust clinical results, underpin Emily Bodnar’s Buy rating for Jasper Therapeutics’ stock.
Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Agios Pharma, and NovoCure. According to TipRanks, Bodnar has an average return of -6.1% and a 27.06% success rate on recommended stocks.
In another report released today, BTIG also reiterated a Buy rating on the stock with a $20.00 price target.